Information Provided By: 
Fly News Breaks for March 15, 2017
AZN, TSRO
Mar 15, 2017 | 06:42 EDT
Citi analyst Robyn Karnauskas says she's defending shares of TESARO (TSRO) after data from AstraZeneca (AZN) led to a selloff. After speaking to TESARO management, Karnauskas believes that olaparib's 30.2 month is an outcome of a sensitivity analysis and not the right comparison to TESARO's niraparib's 22 months. Astra's data do not change the analyst's view that olaparib is not better versus niraparib. She reiterates a Buy rating on TESARO with a $232 price target.
News For TSRO;AZN From the Last 2 Days
AZN
Apr 23, 2024 | 11:16 EDT
Bearish flow noted in AstraZeneca with 3,362 puts trading, or 1.7x expected. Most active are 4/26 weekly 70 puts and May-24 70 calls, with total volume in those strikes near 3,600 contracts. The Put/Call Ratio is 1.72, while ATM IV is up nearly 2 points on the day. Earnings are expected on April 25th.
